Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Choroidal neovascularization regression on fluorescein angiography after VEGF blockade.

Do DV, Greenwald L, Ibrahim M, Sepah Y, Nguyen QD.

Case Rep Ophthalmol. 2012 Sep;3(3):384-8. doi: 10.1159/000338969. Epub 2012 Nov 7.

3.

A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.

Algvere PV, Steén B, Seregard S, Kvanta A.

Acta Ophthalmol. 2008 Aug;86(5):482-9. Epub 2007 Dec 14.

4.
5.

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.

Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group..

Ophthalmology. 2007 Oct;114(10):1868-75. Epub 2007 Jul 12.

PMID:
17628683
6.

Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization.

Khurana RN, Dupas B, Bressler NM.

Ophthalmology. 2010 Jul;117(7):1376-80. doi: 10.1016/j.ophtha.2009.11.039. Epub 2010 May 7.

PMID:
20452027
7.

Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.

Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.

Retina. 2011 Oct;31(9):1841-7. doi: 10.1097/IAE.0b013e31821800a4.

PMID:
21775926
8.

Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.

Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S.

Ophthalmology. 2012 Aug;119(8):1621-7. doi: 10.1016/j.ophtha.2012.02.022. Epub 2012 May 1.

PMID:
22551738
9.

Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.

Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, Maia M, Farah ME, Brito M, Díaz-Llopis M, Rodríguez FJ, Reategui G, Iturralde-Iraola J, Udaondo-Mirete P; Pan-American Collaborative Retina Study Group..

Ophthalmology. 2010 Oct;117(10):1974-81, 1981.e1. doi: 10.1016/j.ophtha.2010.01.056. Epub 2010 May 31.

PMID:
20569989
10.

Antiangiogenic approaches to age-related macular degeneration today.

Bressler NM.

Ophthalmology. 2009 Oct;116(10 Suppl):S15-23. doi: 10.1016/j.ophtha.2009.06.048. Review.

PMID:
19800535
11.

Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.

Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.

Retina. 2011 May;31(5):871-9. doi: 10.1097/IAE.0b013e3182003ca8.

PMID:
21358461
12.

Changes in neovascular choroidal morphology after intravitreal bevacizumab injection: prospective trial on 156 eyes throughout 12-month follow-up.

Costagliola C, Semeraro F, Cipollone U, Rinaldi M, della Corte M, Romano MR.

Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1031-7. doi: 10.1007/s00417-009-1081-y. Epub 2009 Apr 29.

PMID:
19404665
13.

Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study.

Do DV, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, Heier JS, Jefferys JL, Singerman LJ, Solomon SD.

Ophthalmology. 2012 Apr;119(4):771-8. doi: 10.1016/j.ophtha.2011.10.019. Epub 2012 Jan 31.

PMID:
22297028
14.

Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography.

Framme C, Panagakis G, Birngruber R.

Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1671-6. doi: 10.1167/iovs.09-4496. Epub 2009 Oct 29.

PMID:
19875667
15.

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.

Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU.

Graefes Arch Clin Exp Ophthalmol. 2007 Jul;245(7):941-8. Epub 2006 Dec 21.

PMID:
17186262
16.
17.

Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.

Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.

Retina. 2011 Oct;31(9):1812-8. doi: 10.1097/IAE.0b013e31821987a4.

PMID:
21866073
18.

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group..

Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.

PMID:
18827735
19.

Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration.

Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM.

Ophthalmology. 2015 Jan;122(1):153-61. doi: 10.1016/j.ophtha.2014.07.046. Epub 2014 Oct 3.

PMID:
25283060
20.

Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.

Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.

Ophthalmology. 2009 Dec;116(12):2393-9. doi: 10.1016/j.ophtha.2009.05.039. Epub 2009 Oct 7.

PMID:
19815292

Supplemental Content

Support Center